Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Connect Biopharma Holdings LtdCNTB · Entity 6516 | Director | March 16, 2026 | March 16, 2026 |
| Elicio Therapeutics, Inc.ELTX · Entity 299 | Director | August 31, 2026 | September 02, 2026 |
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | SVP, Finance & PAO | March 05, 2019 | March 08, 2019 |
| LAVA Therapeutics NVLVTX · Entity 73047 | Director | November 13, 2025 | November 17, 2025 |
| Serina Therapeutics, Inc.SER · Entity 9581 | Director | June 17, 2026 | June 22, 2026 |
| Vaxart, Inc.VXRT · Entity 6654 | Director | June 16, 2021 | June 17, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Connect Biopharma Holdings Ltd
Report date March 16, 2026 · Filed March 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 10,000 |
Reported balance
Holding disclosure · report date 2026-03-16 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 10,000 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.16 · Expires 2030-11-01 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-16 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: The stock option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.12 · Expires 2032-03-01 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-16 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F1: The stock option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.27 · Expires 2033-03-01 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-16 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F1: The stock option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.18 · Expires 2034-03-01 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-16 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F1: The stock option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.96 · Expires 2035-06-24 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-16 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance Not disclosed F1: The stock option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.50 · Expires 2036-03-02 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-16 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance Not disclosed F2: The stock option fully vests and becomes exercisable on March 2, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option is fully vested and exercisable.
F2: The stock option fully vests and becomes exercisable on March 2, 2027.
Elicio Therapeutics, Inc.
Report date August 31, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.70 · Expires 2036-08-31 | Direct | 21,750 |
Reported balance
After 2026-08-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-31 · Grant · Acquired 21,750 · Balance 21,750 F1: The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders.
Jazz Pharmaceuticals plc
Report date March 05, 2019 · Filed March 08, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 18,385 |
Ending reported balance
After 2019-03-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-03-05 · Tax withholding · Disposed 276 · Balance 18,687 F1: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Row 2 · 2019-03-05 · Tax withholding · Disposed 302 · Balance 18,385 F1: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.
LAVA Therapeutics NV
Report date November 13, 2025 · Filed November 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-11-13 transaction · row 1
1 source rowRow 1 · 2025-11-13 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Disposed of pursuant to that certain Purchase Agreement, dated August 3, 2025, by and between the Issuer and XOMA Royalty Corporation (as amended, the " Purchase Agreement") in exchange for (i) $1.04 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share. |
| Share Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.93 · Expires 2035-02-12 | Direct | 0 |
Reported balance
After 2025-11-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-11-13 · Disposition to issuer · Disposed 33,390 · Balance 0 F2: This option was cancelled pursuant to that certain Purchase Agreement in exchange for cash and CVRs (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to (i) the excess of $1.04 over the per share exercise price of such option multiplied by the total number of shares underlying such in option and (ii) one CVR per share underlying such in-the-money option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to that certain Purchase Agreement, dated August 3, 2025, by and between the Issuer and XOMA Royalty Corporation (as amended, the " Purchase Agreement") in exchange for (i) $1.04 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share.
F2: This option was cancelled pursuant to that certain Purchase Agreement in exchange for cash and CVRs (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to (i) the excess of $1.04 over the per share exercise price of such option multiplied by the total number of shares underlying such in option and (ii) one CVR per share underlying such in-the-money option.
Serina Therapeutics, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.98 · Expires 2036-06-17 | Direct | 15,250 |
Reported balance
After 2026-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-17 · Grant · Acquired 15,250 · Balance 15,250 F2: The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |
| Common StockSEC Table I · non-derivative | Direct | 30,100 |
Reported balance
Holding disclosure · report date 2026-06-17 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 30,100 F1: This row is being reported to update the previously reported number of shares beneficially owned by the Reporting Person and does not reflect an unreported transaction. |
Filing footnotes · ownership attribution and instrument terms
F1: This row is being reported to update the previously reported number of shares beneficially owned by the Reporting Person and does not reflect an unreported transaction.
F2: The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
Vaxart, Inc.
Report date June 16, 2021 · Filed June 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.79 · Expires 2031-06-15 | Direct | 15,097 |
Reported balance
After 2021-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-16 · Grant · Acquired 15,097 · Balance 15,097 F1: The shares subject to this option shall vest on the earlier of the date of the 2022 annual meeting of stockholders of the Issuer and June 16, 2022, the first anniversary of the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest on the earlier of the date of the 2022 annual meeting of stockholders of the Issuer and June 16, 2022, the first anniversary of the date of the grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2026 Filed Sep 2, 2026 20:03 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 21,750 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001267490-26-000010 · wk-form4_1788379379.xml · derivative · entry 1 WILSON KAREN J · CIK 0001267490 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,750 Underlying: Common Stock · 21,750 shares Expires 2036-08-31 F1 · derivative.exercise_date: The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 23:13 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | GrantStock Option (right to buy) · Derivative | 15,250 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001267490-26-000008 · wk-form4_1782169998.xml · derivative · entry 2 WILSON KAREN J · CIK 0001267490 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,250 Underlying: Common Stock · 15,250 shares Expires 2036-06-17 F2 · derivative.exercise_date: The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| June 12, 2026 Filed Jun 15, 2026 14:31 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 5,000 | $1.77 | $8,850.00 |
DisclosureSEC source: 0001267490-26-000006 · wk-form4_1781533906.xml · nonDerivative · entry 2 WILSON KAREN J · CIK 0001267490 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,100 F2 · balance_after: The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.76 per share to a high purchase price of $1.77 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 14:31 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 5,100 | $1.75 | $8,899.50 |
DisclosureSEC source: 0001267490-26-000006 · wk-form4_1781533906.xml · nonDerivative · entry 1 WILSON KAREN J · CIK 0001267490 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,100 F1 · balance_after: The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.745 per share to a high purchase price of $1.75 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price. Read SEC document |
| May 22, 2026 Filed May 26, 2026 20:26 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 10,000 | $1.93 | $19,300.00 |
DisclosureSEC source: 0001267490-26-000004 · wk-form4_1779827204.xml · nonDerivative · entry 2 WILSON KAREN J · CIK 0001267490 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 F2 · price: The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.90 per share to a high purchase price of $1.95 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price. Read SEC document |
| May 21, 2026 Filed May 26, 2026 20:26 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | PurchaseCommon Stock | 10,000 | $1.77 | $17,700.00 |
DisclosureSEC source: 0001267490-26-000004 · wk-form4_1779827204.xml · nonDerivative · entry 1 WILSON KAREN J · CIK 0001267490 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.76 per share to a high purchase price of $1.79 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price. Read SEC document |
| November 13, 2025 Filed Nov 17, 2025 21:30 UTC | LAVA Therapeutics NV LVTX · Entity 73047 | Disposition to issuerShare Options (Right to Buy) · Derivative | 33,390 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0001267490-25-000006 · form4-11172025_041107.xml · derivative · entry 2 WILSON KAREN J · CIK 0001267490 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 33,390 shares Expires 2035-02-12 F2 · derivative.exercise_date: This option was cancelled pursuant to that certain Purchase Agreement in exchange for cash and CVRs (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to (i) the excess of $1.04 over the per share exercise price of such option multiplied by the total number of shares underlying such in option and (ii) one CVR per share underlying such in-the-money option. Read SEC document |
| November 13, 2025 Filed Nov 17, 2025 21:30 UTC | LAVA Therapeutics NV LVTX · Entity 73047 | Disposition to issuerCommon Shares | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001267490-25-000006 · form4-11172025_041107.xml · nonDerivative · entry 1 WILSON KAREN J · CIK 0001267490 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of pursuant to that certain Purchase Agreement, dated August 3, 2025, by and between the Issuer and XOMA Royalty Corporation (as amended, the " Purchase Agreement") in exchange for (i) $1.04 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share. Read SEC document |
| November 07, 2025 Filed Nov 11, 2025 00:30 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.91 | $0.00 |
DisclosureSEC source: 0001267490-25-000003 · wk-form4_1762821015.xml · derivative · entry 1 WILSON KAREN J · CIK 0001267490 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-11-07 F1 · derivative.exercise_date: The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| May 19, 2025 Filed May 20, 2025 20:06 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 7,900 | $0.00 Strike: $5.84 | $0.00 |
DisclosureSEC source: 0001601485-25-000086 · wk-form4_1747771581.xml · derivative · entry 1 WILSON KAREN J · CIK 0001267490 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,900 Underlying: Common Stock · 7,900 shares Expires 2035-05-19 F1 · shares: The stock option shall vest and become exercisable in full on the earlier of (A) May 19, 2026, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. F1 · derivative.exercise_date: The stock option shall vest and become exercisable in full on the earlier of (A) May 19, 2026, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 01:15 UTC | LAVA Therapeutics NV LVTX · Entity 73047 | GrantCommon Shares (Right to Buy) · Derivative | 33,390 | $0.00 Strike: $0.93 | $0.00 |
DisclosureSEC source: 0001415889-25-004532 · form4-02182025_080221.xml · derivative · entry 1 WILSON KAREN J · CIK 0001267490 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,390 Underlying: Common Shares · 33,390 shares Expires 2035-02-12 F1 · derivative.exercise_date: 100% of the shares underlying the option will vest on February 13, 2026, provided the Reporting Person remains in a service relationship with the Issuer or a subsidiary of the Issuer on such vesting date. Read SEC document |
| January 14, 2025 Filed Jan 15, 2025 21:23 UTC | Serina Therapeutics, Inc. SER · Entity 9581 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $4.90 | $0.00 |
DisclosureSEC source: 0001708599-25-000009 · wk-form4_1736976192.xml · derivative · entry 1 WILSON KAREN J · CIK 0001267490 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-01-13 F1 · derivative.exercise_date: The stock options vest in substantially equal yearly installments beginning on the first anniversary of the grant date such that the stock options shall be fully vested on the third anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 21:05 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 4,100 | $0.00 Strike: $5.12 | $0.00 |
DisclosureSEC source: 0001601485-24-000101 · wk-form4_1732568717.xml · derivative · entry 1 WILSON KAREN J · CIK 0001267490 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,100 Underlying: Common Stock · 4,100 shares Expires 2034-11-21 F1 · shares: The stock option shall vest and become exercisable in full on the earlier of (A) November 21, 2025, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. F1 · derivative.exercise_date: The stock option shall vest and become exercisable in full on the earlier of (A) November 21, 2025, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. Read SEC document |
| December 28, 2023 Filed Dec 29, 2023 22:05 UTC | Elicio Therapeutics, Inc. ELTX · Entity 299 | GrantStock Option (right to buy) · Derivative | 4,100 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0001140361-23-060237 · form4.xml · derivative · entry 1 WILSON KAREN J · CIK 0001267490 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,100 Underlying: Common Stock · 4,100 shares Expires 2033-12-28 F1 · shares: The stock option, granted in lieu of the annual equity award under the Issuer's Amended and Restated Non-Employee Director Compensation Policy, vests in full on the earlier of (A) December 28, 2024, the one-year anniversary of the grant date, or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. F1 · derivative.exercise_date: The stock option, granted in lieu of the annual equity award under the Issuer's Amended and Restated Non-Employee Director Compensation Policy, vests in full on the earlier of (A) December 28, 2024, the one-year anniversary of the grant date, or (B) immediately prior to the next annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 21:26 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | GrantCommon Stock · Derivative | 15,000 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0001601485-22-000051 · wf-form4_165515557133787.xml · derivative · entry 1 WILSON KAREN J · CIK 0001267490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: 1.To vest on the earlier of the first anniversary of the date of grant or the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 23:27 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 15,097 | $0.00 Strike: $7.79 | $0.00 |
DisclosureSEC source: 0001437749-21-015113 · rdgdoc.xml · derivative · entry 1 WILSON KAREN J · CIK 0001267490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,097 Underlying: Common stock · 15,097 shares Expires 2031-06-15 F1 · derivative.exercise_date: The shares subject to this option shall vest on the earlier of the date of the 2022 annual meeting of stockholders of the Issuer and June 16, 2022, the first anniversary of the date of the grant. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 21:09 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $15.01 | $0.00 |
DisclosureSEC source: 0001567619-21-005971 · doc1.xml · derivative · entry 1 WILSON KAREN J · CIK 0001267490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-03-07 F1 · derivative.exercise_date: To vest on the earlier of the first anniversary of the date of grant or the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 00:24 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | ConversionConvertible Promissory Note · Derivative | Not disclosed | $0.00 Strike: $16.00 | $216,569.87 |
DisclosureSEC source: 0001567619-21-003192 · doc1.xml · derivative · entry 2 WILSON KAREN J · CIK 0001267490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · Not disclosed shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The convertible promissory note converted immediately prior to the consummation of the IPO into Common Stock. F2 · derivative.expiration_date: The convertible promissory note ("Convertible Note") had a maturity date of June 1, 2021 and the principal amount of the Convertible Note converted upon the closing of the IPO into Common Shares at a conversion price equal to $18.00 per Common Share. Read SEC document |
| February 09, 2021 Filed Feb 12, 2021 00:24 UTC | Elicio Therapeutics, Inc. ANGN · Entity 299 | ConversionCommon Stock | 18,718 | $11.57 | $216,567.26 |
DisclosureSEC source: 0001567619-21-003192 · doc1.xml · nonDerivative · entry 1 WILSON KAREN J · CIK 0001267490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 12:17 UTC | Vaxart, Inc. VXRT · Entity 6654 | GrantStock Option (right to buy) · Derivative | 65,700 | $0.00 Strike: $6.95 | $0.00 |
DisclosureSEC source: 0001437749-20-018801 · rdgdoc.xml · derivative · entry 1 WILSON KAREN J · CIK 0001267490 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,700 Underlying: Common Stock · 65,700 shares Expires 2030-08-24 F1 · derivative.exercise_date: The shares subject to this option shall vest annually over three years from the vesting commencement date of August 25, 2020, the date of the grantee's appointment as a director of Vaxart, Inc. Read SEC document |
| March 05, 2019 Filed Mar 8, 2019 00:11 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 302 | $135.82 | $41,017.64 |
DisclosureSEC source: 0001765581-19-000039 · edgardoc.xml · nonDerivative · entry 2 WILSON KAREN J · CIK 0001267490 · SVP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,385 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 05, 2019 Filed Mar 8, 2019 00:11 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 276 | $135.82 | $37,486.32 |
DisclosureSEC source: 0001765581-19-000039 · edgardoc.xml · nonDerivative · entry 1 WILSON KAREN J · CIK 0001267490 · SVP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,687 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 00:43 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 8,174 | $0.00 Strike: $140.03 | $0.00 |
DisclosureSEC source: 0001765581-19-000027 · edgardoc.xml · derivative · entry 3 WILSON KAREN J · CIK 0001267490 · SVP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,174 Underlying: Ordinary Shares · 8,174 shares Expires 2029-02-27 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 28, 2019, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 00:43 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantIncentive Stock Option (right to buy) · Derivative | 576 | $0.00 Strike: $140.03 | $0.00 |
DisclosureSEC source: 0001765581-19-000027 · edgardoc.xml · derivative · entry 2 WILSON KAREN J · CIK 0001267490 · SVP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 576 Underlying: Ordinary Shares · 576 shares Expires 2029-02-27 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 28, 2019, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 00:43 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-19-000027 · edgardoc.xml · nonDerivative · entry 1 WILSON KAREN J · CIK 0001267490 · SVP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,963 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| February 26, 2019 Filed Feb 27, 2019 23:40 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 230 | $127.76 | $29,384.80 |
DisclosureSEC source: 0001765581-19-000010 · edgardoc.xml · nonDerivative · entry 2 WILSON KAREN J · CIK 0001267490 · SVP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,463 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 23:40 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 310 | $126.25 | $39,137.50 |
DisclosureSEC source: 0001765581-19-000010 · edgardoc.xml · nonDerivative · entry 1 WILSON KAREN J · CIK 0001267490 · SVP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,693 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. F2 · balance_after: Includes 173 ordinary shares acquired on May 31, 2018 and 73 ordinary shares acquired on November 30, 2018 under a Section 423 Employee Stock Purchase Plan. Read SEC document |
| May 11, 2018 Filed May 15, 2018 21:27 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 54 | $165.01 | $8,910.27 |
DisclosureSEC source: 0001232524-18-000103 · edgardoc.xml · nonDerivative · entry 2 WILSON KAREN J · CIK 0001267490 · SVP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,757 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| May 11, 2018 Filed May 15, 2018 21:27 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 3,706 | $165.00 | $611,490.00 |
DisclosureSEC source: 0001232524-18-000103 · edgardoc.xml · nonDerivative · entry 1 WILSON KAREN J · CIK 0001267490 · SVP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,811 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 10, 2018 Filed Apr 12, 2018 20:25 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 3,899 | $155.00 | $604,345.00 |
DisclosureSEC source: 0001232524-18-000076 · edgardoc.xml · nonDerivative · entry 1 WILSON KAREN J · CIK 0001267490 · SVP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,517 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 21:10 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 302 | $143.39 | $43,303.78 |
DisclosureSEC source: 0001232524-18-000060 · edgardoc.xml · nonDerivative · entry 1 WILSON KAREN J · CIK 0001267490 · SVP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,416 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:39 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 7,319 | $0.00 Strike: $140.67 | $0.00 |
DisclosureSEC source: 0001232524-18-000049 · edgardoc.xml · derivative · entry 3 WILSON KAREN J · CIK 0001267490 · SVP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,319 Underlying: Ordinary Shares · 7,319 shares Expires 2028-02-29 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 1, 2018, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:39 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantIncentive Stock Option (right to buy) · Derivative | 681 | $0.00 Strike: $140.67 | $0.00 |
DisclosureSEC source: 0001232524-18-000049 · edgardoc.xml · derivative · entry 2 WILSON KAREN J · CIK 0001267490 · SVP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 681 Underlying: Ordinary Shares · 681 shares Expires 2028-02-29 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 1, 2018, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:39 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 3,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001232524-18-000049 · edgardoc.xml · nonDerivative · entry 1 WILSON KAREN J · CIK 0001267490 · SVP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,718 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2018, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 22:29 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 324 | $143.80 | $46,591.20 |
DisclosureSEC source: 0001232524-18-000030 · edgardoc.xml · nonDerivative · entry 2 WILSON KAREN J · CIK 0001267490 · SVP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,518 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 22:29 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 537 | $147.44 | $79,175.28 |
DisclosureSEC source: 0001232524-18-000030 · edgardoc.xml · nonDerivative · entry 1 WILSON KAREN J · CIK 0001267490 · SVP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,842 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. F2 · balance_after: Includes 173 ordinary shares acquired on May 31, 2017 and 73 ordinary shares acquired on November 30, 2017 under a Section 423 Employee Stock Purchase Plan. Read SEC document |
| April 27, 2017 Filed Apr 27, 2017 23:10 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,275 | $160.00 | $204,000.00 |
DisclosureSEC source: 0001232524-17-000087 · edgardoc.xml · nonDerivative · entry 1 WILSON KAREN J · CIK 0001267490 · SVP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,133 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 10, 2017 Filed Apr 12, 2017 00:29 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,750 | $0.00 Strike: $59.13 | $0.00 |
DisclosureSEC source: 0001232524-17-000082 · edgardoc.xml · derivative · entry 6 WILSON KAREN J · CIK 0001267490 · SVP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,750 shares Expires 2023-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · derivative.exercise_date: This non-qualified stock option is part of an option granted on March 5, 2013 that consisted of an incentive stock option exercisable for 750 ordinary shares and this non-qualified stock option exercisable for 11,250 ordinary shares. The options were fully vested as of March 5, 2017. Read SEC document |
| April 10, 2017 Filed Apr 12, 2017 00:29 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 6,708 | $0.00 Strike: $46.83 | $0.00 |
DisclosureSEC source: 0001232524-17-000082 · edgardoc.xml · derivative · entry 5 WILSON KAREN J · CIK 0001267490 · SVP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,708 shares Expires 2022-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: This non-qualified stock option is part of an option granted on August 9, 2012 that consisted of an incentive stock option exercisable for 3,048 ordinary shares and this non-qualified stock option exercisable for 26,952 ordinary shares. The options were fully vested as of August 9, 2016. Read SEC document |
| April 10, 2017 Filed Apr 12, 2017 00:29 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 6,708 | $152.24 | $1,021,225.92 |
DisclosureSEC source: 0001232524-17-000082 · edgardoc.xml · nonDerivative · entry 4 WILSON KAREN J · CIK 0001267490 · SVP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,408 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 10, 2017 Filed Apr 12, 2017 00:29 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 6,708 | $46.83 | $314,135.64 |
DisclosureSEC source: 0001232524-17-000082 · edgardoc.xml · nonDerivative · entry 3 WILSON KAREN J · CIK 0001267490 · SVP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,116 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 10, 2017 Filed Apr 12, 2017 00:29 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 4,750 | $152.24 | $723,140.00 |
DisclosureSEC source: 0001232524-17-000082 · edgardoc.xml · nonDerivative · entry 2 WILSON KAREN J · CIK 0001267490 · SVP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,408 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 10, 2017 Filed Apr 12, 2017 00:29 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 4,750 | $59.13 | $280,867.50 |
DisclosureSEC source: 0001232524-17-000082 · edgardoc.xml · nonDerivative · entry 1 WILSON KAREN J · CIK 0001267490 · SVP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,158 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 08, 2017 Filed Mar 8, 2017 22:47 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 750 | $0.00 Strike: $59.13 | $0.00 |
DisclosureSEC source: 0001232524-17-000076 · edgardoc.xml · derivative · entry 5 WILSON KAREN J · CIK 0001267490 · SVP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 750 shares Expires 2023-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to this option vested over four years measured from the grant date, March 5, 2013, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 08, 2017 Filed Mar 8, 2017 22:47 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,896 | $0.00 Strike: $46.83 | $0.00 |
DisclosureSEC source: 0001232524-17-000076 · edgardoc.xml · derivative · entry 4 WILSON KAREN J · CIK 0001267490 · SVP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,896 shares Expires 2022-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to this option vested over four years measured from the grant date, August 9, 2012, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 08, 2017 Filed Mar 8, 2017 22:47 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 750 | $59.13 | $44,347.50 |
DisclosureSEC source: 0001232524-17-000076 · edgardoc.xml · nonDerivative · entry 3 WILSON KAREN J · CIK 0001267490 · SVP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2017 Filed Mar 8, 2017 22:47 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 2,896 | $46.83 | $135,619.68 |
DisclosureSEC source: 0001232524-17-000076 · edgardoc.xml · nonDerivative · entry 2 WILSON KAREN J · CIK 0001267490 · SVP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,658 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 22:47 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 563 | $132.81 | $74,772.03 |
DisclosureSEC source: 0001232524-17-000076 · edgardoc.xml · nonDerivative · entry 1 WILSON KAREN J · CIK 0001267490 · SVP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,762 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 23:57 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 7,781 | $0.00 Strike: $136.18 | $0.00 |
DisclosureSEC source: 0001232524-17-000063 · edgardoc.xml · derivative · entry 3 WILSON KAREN J · CIK 0001267490 · SVP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,781 Underlying: Ordinary Shares · 7,781 shares Expires 2027-03-01 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 2, 2017, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 23:57 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantIncentive Stock Option (right to buy) · Derivative | 969 | $0.00 Strike: $136.18 | $0.00 |
DisclosureSEC source: 0001232524-17-000063 · edgardoc.xml · derivative · entry 2 WILSON KAREN J · CIK 0001267490 · SVP, Finance & PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 969 Underlying: Ordinary Shares · 969 shares Expires 2027-03-01 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 2, 2017, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.